The compelling Phase 2 data positions divesiran as a potential best-in-class therapy for PV, a large underserved market (~150K US patients). Watch for Phase 3 start in 1H 2027 and potential partnership or licensing interest. The stock is likely to see a strong positive reaction; monitor the conference call for further details on regulatory path and commercial strategy.
Price Chart
Executive Summary
Silence Therapeutics announced positive topline Phase 2 SANRECO trial results for divesiran in polycythemia vera (PV). The primary endpoint was met with a significantly higher proportion of clinical responders (88% vs 19% placebo; p<0.0001), and both Q6W and Q12W dosing showed strong efficacy (93.8% and 81.3% response rates, respectively). The company plans to initiate a Phase 3 trial in 1H 2027, supporting divesiran's potential as a best-in-class siRNA therapy for PV.
Key Facts
- Primary endpoint met: 88% clinical responders for divesiran vs 19% placebo (p<0.0001), placebo-adjusted response rate 69%.
- Dose groups: 93.8% response at Q6W and 81.3% at Q12W.
- Key secondary endpoint: mean phlebotomies reduced to 0.2 (divesiran) vs 2.1 (placebo) during weeks 0-36 (p<0.0001).
- Safety well-tolerated with no new findings; injection site reactions infrequent and self-limiting.
- Phase 3 trial evaluating divesiran Q12W vs placebo expected to initiate in first half of 2027.
Financial Impact
No financial data reported; clinical-stage biotech with no revenue. Positive data could significantly increase probability of success and potential partnership value.
Risk Factors
- Phase 3 trial failure or safety issues could derail development.
- Regulatory hurdles for siRNA therapy in PV.
- Competition from existing therapies (JAK inhibitors, interferon) and other pipeline candidates.
- Need for additional capital to fund Phase 3 and commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-341293 |
| Document: d12947dex991.htm | 0001193125-26-341293 |
| Document: d12947dex992.htm | 0001193125-26-341293 |
| Document: 0001193125-26-341293-index-headers.html | 0001193125-26-341293 |
| Document: 0001193125-26-341293-index.html | 0001193125-26-341293 |
| Document: 0001193125-26-341293.txt | 0001193125-26-341293 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 424B5 | $14.72 $13.55 | ▲ +7.95% | ▲ +6.89% | $10.55 (+28.33%) |
Aug 10, 2026 7w ago | 8-K | $15.43 $13.69 | ▼ −11.28% | ▼ −10.36% | $10.55 (−31.63%) |
Aug 10, 2026 7w ago | 8-K | $15.43 $13.69 | ▼ −11.28% | ▼ −10.36% | $10.55 (−31.63%) |
Jun 23, 2026 14w ago | 8-K | $9.16 $11.83 | ▲ +29.15% | ▲ +27.22% | $10.55 (+15.17%) |
Mar 5, 2026 30w ago | 8-K | $5.50 $5.94 | ▲ +8.00% | ▲ +11.79% | $10.55 (+91.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access